HC Wainwright & Co. Initiates Coverage On Processa Pharma with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Processa Pharma (NASDAQ:PCSA) with a Buy rating and a price target of $8.

April 25, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Processa Pharma receives a Buy rating from HC Wainwright & Co. with a price target of $8.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target significantly above the current trading price is likely to generate positive sentiment among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100